Trial site
Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center
Yokohama, Kanagawa 241-8515, JapanNot linked to an institution yet
- 10running trials
- 4closed trials
The trials here
What the 14 trials at this site are about, from their registry records.
- Phase
- Phase 39 trials
- Phase 23 trials
- Phase 11 trial
- Phase 1/21 trial
- Status
- Active, not recruiting5 trials
- Recruiting4 trials
- Completed3 trials
- Not yet recruiting1 trial
- Terminated1 trial
- Lead sponsor
- Amgen11 trials
- National Cancer Center Hospital East1 trial
- National Cancer Center, Japan1 trial
- Toray Industries, Inc1 trial
Running trials
Not yet recruiting
A Phase II, Investigator-Initiated Exploratory Study of Sacituzumab Tirumotecan for Previously Treated Unresectable Thymic Carcinomas
NCT07750353· Phase 2· National Cancer Center, Japan· Source
Contact: Shuji Murakami
Active, not recruiting
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
NCT06745323· Phase 2· Amgen· Source
Recruiting
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
NCT06252649· Phase 3· Amgen· Source
Active, not recruiting
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT06211036· Phase 3· Amgen· Source
Active, not recruiting
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
NCT06360354· Phase 1· Amgen· Source
Active, not recruiting
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774· Phase 3· Amgen· Source
Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356· Phase 3· Amgen· Source
Recruiting
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
NCT06038578· Phase 2· Toray Industries, Inc· Source
Contact: Principal Investigator
Active, not recruiting
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
NCT05740566· Phase 3· Amgen· Source
Recruiting
TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer
NCT05646511· Phase 3· National Cancer Center Hospital East· Source
Contact: Manabu Shiozawa, Dr.
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error